This inventor holds 1 USPTO granted patent. Top assignee: Cytel Corporation. Active years: 1998.
Company Filing History:
Years Active: 1998
Title: Van Tsai: Innovator in Ex Vivo Therapy
Introduction
Van Tsai is a notable inventor based in San Diego, CA. He has made significant contributions to the field of immunotherapy, particularly through his innovative methods for ex vivo therapy. His work focuses on enhancing the activation of cytotoxic T lymphocytes (CTL), which are crucial for effective cancer treatment.
Latest Patents
Van Tsai holds a patent for "Methods for ex vivo therapy using peptide-loaded antigen presenting." This patent outlines methods for activating CTLs in vitro, which are then utilized for therapy in vivo. Additionally, it presents a novel approach for selectively killing specific CTLs in vivo using modified antigen presenting cells.
Career Highlights
Van Tsai is currently employed at Cytel Corporation, where he continues to advance his research in immunotherapy. His work has the potential to significantly impact cancer treatment methodologies and improve patient outcomes.
Collaborations
He collaborates with esteemed colleagues such as Esteban Celis and Ralph T Kubo, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Van Tsai's contributions to ex vivo therapy and his innovative approaches to activating CTLs highlight his role as a leading inventor in the field of immunotherapy. His work at Cytel Corporation and his patent demonstrate his commitment to advancing medical science and improving therapeutic strategies.